From baseline, patients treated with AXS-12 had an 83% reduction in cataplexy attacks at the end of 5 weeks compared with a ...

The link between narcolepsy and cardiovascular disease (CVD) was strengthened by new evidence that the relationship applied ...

For the next in our series of conditions GPs might rarely encounter, Neurology consultant Dr Clare Bolton provides an ...

Jazz is being accused of anti-competitive practices regarding its narcolepsy drug, as generic competitors emerge on the ...

Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today presented at the 24th Annual Needham Virtual Healthcare Conference.

Sleep is our cornerstone for physical and mental health, yet for millions, it remains elusive due to sleep disorders. These conditions disrupt regular sleep patterns, leading to a host of ...

Among patients with narcolepsy, AXS-12 (reboxetine) vs placebo significantly reduced the frequency of cataplexy attacks.

Analysts at BMO Capital Markets said Centessa’s orexin receptor agonist has “best-in-class” potential for narcolepsy, putting ...